• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在日常临床实践中通过寻找和限制炎症触发因素改善溃疡性结肠炎的控制情况。

Improvement of ulcerative colitis control by searching and restricting of inflammatory trigger factors in daily clinical practice.

作者信息

Tsai Kun-Yu, You Jeng-Fu, Tsai Tzong-Yun, Chern Yih Jong, Hsu Yu-Jen, Huang Shu-Huan, Tsai Wen-Sy

机构信息

Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan, Republic of China.

School of Medicine, Chang Gung University, Taoyuan, Taiwan, Republic of China.

出版信息

Intest Res. 2023 Jan;21(1):100-109. doi: 10.5217/ir.2021.00110. Epub 2022 Nov 14.

DOI:10.5217/ir.2021.00110
PMID:36366932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9911270/
Abstract

BACKGROUND/AIMS: Exacerbating factors of ulcerative colitis (UC) are multiple and complex with individual influence. We aimed to evaluate the efficacy of disease control by searching and restricting inflammation trigger factors of UC relapse individually in daily clinical practice.

METHODS

Both patients with UC history or new diagnosis were asked to avoid dairy products at first doctor visit. Individual-reported potential trigger factors were restricted when UC flared up (Mayo endoscopy score ≥1) from remission status. The remission rate, duration to remission and medication were analyzed between the groups of factor restriction complete, incomplete and unknown.

RESULTS

The total remission rate was 91.7% of 108 patients with complete restriction of dairy product. The duration to remission of UC history group was significantly longer than that of new diagnosis group (88.5 days vs. 43.4 days, P=0.006) in patients with initial endoscopic score 2-3, but no difference in patients with score 1. After first remission, the inflammation trigger factors in 161 relapse episodes of 72 patients were multiple and personal. Milk/dairy products, herb medicine/Chinese tonic food and dietary supplement were the common factors, followed by psychological issues, non-dietary factors (smoking cessation, cosmetic products) and discontinuation of medication by patients themselves. Factor unknown accounted for 14.1% of patients. The benefits of factor complete restriction included shorter duration to remission (P<0.001), less steroid and biological agent use (P=0.022) when compared to incomplete restriction or factor unknown group.

CONCLUSIONS

Restriction of dairy diet first then searching and restricting trigger factors personally if UC relapse can improve the disease control and downgrade the medication usage of UC patients in daily clinical practice.

摘要

背景/目的:溃疡性结肠炎(UC)的加重因素多样且复杂,存在个体差异。我们旨在通过在日常临床实践中逐一寻找并限制UC复发的炎症触发因素,来评估疾病控制的效果。

方法

有UC病史或新诊断的患者在首次就诊时均被要求避免食用乳制品。当UC从缓解状态发作时(梅奥内镜评分≥1),对个体报告的潜在触发因素进行限制。分析因素限制完全、不完全和未知组之间的缓解率、缓解持续时间和用药情况。

结果

108例完全限制乳制品的患者总缓解率为91.7%。初始内镜评分为2 - 3分的患者中,UC病史组的缓解持续时间显著长于新诊断组(88.5天对43.4天,P = 0.006),但内镜评分为1分的患者中无差异。首次缓解后,72例患者的161次复发事件中的炎症触发因素多样且因人而异。牛奶/乳制品、草药/中式滋补食品和膳食补充剂是常见因素,其次是心理问题、非饮食因素(戒烟、化妆品)以及患者自行停药。因素未知的患者占14.1%。与因素限制不完全或未知组相比,因素完全限制的益处包括缓解持续时间更短(P < 0.001)、类固醇和生物制剂使用更少(P = 0.022)。

结论

在日常临床实践中,先限制乳制品饮食,然后在UC复发时逐一寻找并限制触发因素,可改善UC患者的疾病控制并降低用药量。

相似文献

1
Improvement of ulcerative colitis control by searching and restricting of inflammatory trigger factors in daily clinical practice.在日常临床实践中通过寻找和限制炎症触发因素改善溃疡性结肠炎的控制情况。
Intest Res. 2023 Jan;21(1):100-109. doi: 10.5217/ir.2021.00110. Epub 2022 Nov 14.
2
Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes.溃疡性结肠炎的内镜下黏膜愈合和组织学缓解:对临床、生活质量及经济结局的系统文献综述
Curr Med Res Opin. 2022 Sep;38(9):1531-1541. doi: 10.1080/03007995.2022.2081453. Epub 2022 Jun 11.
3
Different therapy for different types of ulcerative colitis in China.中国针对不同类型溃疡性结肠炎的不同治疗方法。
World J Gastroenterol. 2004 May 15;10(10):1513-20. doi: 10.3748/wjg.v10.i10.1513.
4
Dietary interventions for induction and maintenance of remission in inflammatory bowel disease.用于诱导和维持炎症性肠病缓解的饮食干预措施。
Cochrane Database Syst Rev. 2019 Feb 8;2(2):CD012839. doi: 10.1002/14651858.CD012839.pub2.
5
Evaluating clinical, dietary, and psychological risk factors for relapse of ulcerative colitis in clinical, endoscopic, and histological remission.评估临床、内镜及组织学缓解期溃疡性结肠炎复发的临床、饮食及心理风险因素。
J Gastroenterol Hepatol. 2017 Oct;32(10):1698-1705. doi: 10.1111/jgh.13770.
6
Dietary beliefs and information resources of ulcerative colitis patients in clinical remission: A cross-sectional survey in Taiwan.台湾溃疡性结肠炎缓解期患者的饮食信念和信息资源:一项横断面调查。
Clin Nutr ESPEN. 2022 Oct;51:430-436. doi: 10.1016/j.clnesp.2022.07.005. Epub 2022 Jul 21.
7
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.与溃疡性结肠炎相关的泛发性坏疽性脓皮病:英夫利昔单抗和硫唑嘌呤治疗成功
Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.
8
Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.甲氨蝶呤并不优于安慰剂在溃疡性结肠炎中维持无激素缓解或缓解。
Gastroenterology. 2018 Oct;155(4):1098-1108.e9. doi: 10.1053/j.gastro.2018.06.046. Epub 2018 Jun 30.
9
Patients with longstanding ulcerative colitis in remission do not have more irritable bowel syndrome-like symptoms than controls.处于缓解期的长期溃疡性结肠炎患者并不比对照组有更多肠易激综合征样症状。
BMC Gastroenterol. 2016 Nov 24;16(1):139. doi: 10.1186/s12876-016-0553-x.
10
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.美沙拉嗪颗粒对已实现糖皮质激素诱导的溃疡性结肠炎缓解的患者的长期益处。
Dig Dis Sci. 2016 Jan;61(1):221-9. doi: 10.1007/s10620-015-3866-7. Epub 2015 Nov 12.

引用本文的文献

1
Comments on Oral Sulfate Solution Is as Effective as Polyethylene Glycol with Ascorbic Acid in a Split Method for Bowel Preparation in Patients with Inactive Ulcerative Colitis: A Randomized, Multicenter, and Single-Blind Clinical Trial.关于口服硫酸盐溶液在非活动性溃疡性结肠炎患者肠道准备的分段法中与聚乙二醇加抗坏血酸效果相同的评论:一项随机、多中心、单盲临床试验
Gut Liver. 2024 Jan 15;18(1):192-193. doi: 10.5009/gnl230355. Epub 2023 Nov 30.

本文引用的文献

1
Dietary Strategies for Maintenance of Clinical Remission in Inflammatory Bowel Diseases: Are We There Yet?炎症性肠病临床缓解维持的饮食策略:我们做到了吗?
Nutrients. 2020 Jul 7;12(7):2018. doi: 10.3390/nu12072018.
2
Probiotics for maintenance of remission in ulcerative colitis.用于维持溃疡性结肠炎缓解的益生菌。
Cochrane Database Syst Rev. 2020 Mar 4;3(3):CD007443. doi: 10.1002/14651858.CD007443.pub3.
3
Nutritional approach as therapeutic manipulation in inflammatory bowel disease.营养疗法作为炎症性肠病的治疗手段
Intest Res. 2019 Oct;17(4):463-475. doi: 10.5217/ir.2019.00078. Epub 2019 Oct 28.
4
Diet in the Pathogenesis and Management of Ulcerative Colitis; A Review of Randomized Controlled Dietary Interventions.溃疡性结肠炎的发病机制和治疗中的饮食;随机对照饮食干预的综述。
Nutrients. 2019 Jun 30;11(7):1498. doi: 10.3390/nu11071498.
5
Implications of the Westernized Diet in the Onset and Progression of IBD.西式饮食对炎症性肠病发病和进展的影响。
Nutrients. 2019 May 8;11(5):1033. doi: 10.3390/nu11051033.
6
Influence of Environmental Factors in the Development and Outcomes of Inflammatory Bowel Disease.环境因素对炎症性肠病发生发展及预后的影响
Gastroenterol Hepatol (N Y). 2019 Feb;15(2):72-82.
7
European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease.欧洲克罗恩病和结肠炎组织炎症性肠病补充医学和心理治疗专题评论。
J Crohns Colitis. 2019 May 27;13(6):673-685e. doi: 10.1093/ecco-jcc/jjz051.
8
Ultra-Processed Foods: Definitions and Policy Issues.超加工食品:定义与政策问题
Curr Dev Nutr. 2018 Sep 14;3(2):nzy077. doi: 10.1093/cdn/nzy077. eCollection 2019 Feb.
9
Ultra-processed foods: what they are and how to identify them.超加工食品:它们是什么以及如何识别它们。
Public Health Nutr. 2019 Apr;22(5):936-941. doi: 10.1017/S1368980018003762. Epub 2019 Feb 12.
10
Dietary interventions for induction and maintenance of remission in inflammatory bowel disease.用于诱导和维持炎症性肠病缓解的饮食干预措施。
Cochrane Database Syst Rev. 2019 Feb 8;2(2):CD012839. doi: 10.1002/14651858.CD012839.pub2.